These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 16495197

  • 1. Estimating the association between SF-12 responses and EQ-5D utility values by response mapping.
    Gray AM, Rivero-Arias O, Clarke PM.
    Med Decis Making; 2006; 26(1):18-29. PubMed ID: 16495197
    [Abstract] [Full Text] [Related]

  • 2. Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome.
    Rivero-Arias O, Ouellet M, Gray A, Wolstenholme J, Rothwell PM, Luengo-Fernandez R.
    Med Decis Making; 2010; 30(3):341-54. PubMed ID: 19858500
    [Abstract] [Full Text] [Related]

  • 3. Mapping EQ-5D utility scores from the PedsQL™ generic core scales.
    Khan KA, Petrou S, Rivero-Arias O, Walters SJ, Boyle SE.
    Pharmacoeconomics; 2014 Jul; 32(7):693-706. PubMed ID: 24715604
    [Abstract] [Full Text] [Related]

  • 4. Probabilistic mapping of descriptive health status responses onto health state utilities using Bayesian networks: an empirical analysis converting SF-12 into EQ-5D utility index in a national US sample.
    Le QA, Doctor JN.
    Med Care; 2011 May; 49(5):451-60. PubMed ID: 21422961
    [Abstract] [Full Text] [Related]

  • 5. Probabilistic mapping of the health status measure SF-12 onto the health utility measure EQ-5D using the US-population-based scoring models.
    Le QA.
    Qual Life Res; 2014 Mar; 23(2):459-66. PubMed ID: 24026631
    [Abstract] [Full Text] [Related]

  • 6. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
    Hawton A, Green C, Telford C, Zajicek J, Wright D.
    Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
    [Abstract] [Full Text] [Related]

  • 7. Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.
    Chen G, Garcia-Gordillo MA, Collado-Mateo D, Del Pozo-Cruz B, Adsuar JC, Cordero-Ferrera JM, Abellán-Perpiñán JM, Sánchez-Martínez FI.
    Patient; 2018 Dec; 11(6):665-675. PubMed ID: 29876865
    [Abstract] [Full Text] [Related]

  • 8. Mapping analysis to predict EQ-5D-5 L utility values based on the Oxford Hip Score (OHS) and Oxford Knee Score (OKS) questionnaires in the Spanish population suffering from lower limb osteoarthritis.
    Martín-Fernández J, Morey-Montalvo M, Tomás-García N, Martín-Ramos E, Muñoz-García JC, Polentinos-Castro E, Rodríguez-Martínez G, Arenaza JC, García-Pérez L, Magdalena-Armas L, Bilbao A.
    Health Qual Life Outcomes; 2020 Jun 15; 18(1):184. PubMed ID: 32539838
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D.
    Lamu AN, Olsen JA.
    Qual Life Res; 2018 Nov 15; 27(11):2823-2839. PubMed ID: 30173314
    [Abstract] [Full Text] [Related]

  • 13. Estimating preference-based EQ-5D health state utilities or item responses from neuropathic pain scores.
    Gu NY, Bell C, Botteman MF, Ji X, Carter JA, van Hout B.
    Patient; 2012 Nov 15; 5(3):185-97. PubMed ID: 22765255
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Mapping SF-36 onto the EQ-5D index: how reliable is the relationship?
    Rowen D, Brazier J, Roberts J.
    Health Qual Life Outcomes; 2009 Mar 31; 7():27. PubMed ID: 19335878
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Mapping MOS-HIV to HUI3 and EQ-5D-3L in Patients With HIV.
    Joyce VR, Sun H, Barnett PG, Bansback N, Griffin SC, Bayoumi AM, Anis AH, Sculpher M, Cameron W, Brown ST, Holodniy M, Owens DK.
    MDM Policy Pract; 2017 Mar 31; 2(2):2381468317716440. PubMed ID: 30288427
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.